Background: This study will appraise the clinical efficacy of sertraline in the treatment of depression caused by Alzheimer disease (AD). Methods: Comprehensive searches in PUBMED, EMBASE, Cochrane Library, Scopus, AMED, CNKI, and WANGFANG will be performed from inception to the present without language restriction. In addition, other sources will also be searched to avoid losing more potential studies. We will only consider randomized controlled trials that examined the efficacy of sertraline for depression in patients with AD. Two team members will independently undertake literature selection, data collection, and risk of bias assessment. We will use Cochrane Risk of Bias Tool to assess the risk of bias for each eligible trial, and will utilize RevMan 5.3 software to carry out data analysis. Results: This study will recapitulate high-quality evidence to assess the efficacy of sertraline for the treatment of depression following AD. Conclusion: The findings of this study will help to determine whether or not sertraline is effective for the treatment of depression after AD. OSF registration: osf.io/f29v6.
展开▼
机译：背景：本研究将评估塞拉林素治疗阿尔茨海默病（AD）抑郁症的临床疗效。方法：在综合搜索中搜索，embase，Cochrane图书馆，Scopus，amed，CNKI和Wangfang将从开始到现在的情况下进行，没有语言限制。此外，还将搜索其他来源以避免失去更多潜在的研究。我们只会考虑随机对照试验，该试验检测塞拉尔胺对广告患者抑郁症的疗效。两个团队成员将独立进行文学选择，数据收集和偏见评估的风险。我们将使用Cochrane Birt Es Bias工具来评估每个符合条件的试验的偏见风险，并将利用Revman 5.3软件进行数据分析。结果：本研究将重新承载高质量的证据，以评估塞拉林素用于治疗广告后抑郁症的疗效。结论：本研究的结果将有助于确定萨拉林素是否对AD抑郁症的治疗有效。 OSF注册：OSF.IO/F29V6。
展开▼
